Analyst Suggests Life Technologies Could Be LBO Target | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Macquarie Capital analyst Jon Groberg issued a research note on Life Technologies today saying that the firm is "the most undervalued asset in the Life Sciences space" and suggested it could be the target of a leveraged buyout.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.